Fred Grossman Purchases 2,710 Shares of Coya Therapeutics, Inc. Stock
COYA Stock | 6.65 0.27 4.23% |
About 72 percent of all Coya Therapeutics,'s investors are curious in acquiring. The analysis of the overall investor sentiment regarding Coya Therapeutics, Common suggests that a large number of traders are confidant. The current market sentiment, together with Coya Therapeutics,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Coya Therapeutics, Common stock news signals to limit their universe of possible portfolio assets.
Coya |
Coya Therapeutics, Inc. insider Fred Grossman purchased 2,710 shares of the businesss stock in a transaction that occurred on Monday, November 11th. The stock was bought at an average price of 7.37 per share, for a total transaction of 19,972.70. Following the purchase, the insider now directly owns 2,710 shares
Read at thelincolnianonline.com
Coya Therapeutics, Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Coya Therapeutics, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Coya Therapeutics, Fundamental Analysis
We analyze Coya Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coya Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coya Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Coya Therapeutics, is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Coya Therapeutics, Common Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Coya Therapeutics, stock to make a market-neutral strategy. Peer analysis of Coya Therapeutics, could also be used in its relative valuation, which is a method of valuing Coya Therapeutics, by comparing valuation metrics with similar companies.
Peers
Coya Therapeutics, Related Equities
CUE | Cue Biopharma | 11.93 | ||||
TERN | Terns Pharmaceuticals | 7.82 | ||||
STRO | Sutro Biopharma | 3.46 | ||||
TFFP | Tff Pharmaceuticals | 3.33 | ||||
TCRX | Tscan Therapeutics | 2.80 | ||||
ABOS | Acumen Pharmaceuticals | 2.73 | ||||
INZY | Inozyme Pharma | 2.64 | ||||
OPT | Opthea | 1.83 | ||||
CNTA | Centessa Pharmaceuticals | 1.73 | ||||
NAMSW | NewAmsterdam Pharma | 1.68 | ||||
DAWN | Day One | 1.33 | ||||
LTRN | Lantern Pharma | 1.30 | ||||
GANX | Gain Therapeutics | 0.58 | ||||
HLVX | Hillevax | 0.52 | ||||
FENC | Fennec Pharmaceuticals | 0.50 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
CGTX | Cognition Therapeutics | 2.44 | ||||
INAB | In8bio | 3.23 | ||||
DRMA | Dermata Therapeutics | 4.35 |
Complementary Tools for Coya Stock analysis
When running Coya Therapeutics,'s price analysis, check to measure Coya Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coya Therapeutics, is operating at the current time. Most of Coya Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Coya Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coya Therapeutics,'s price. Additionally, you may evaluate how the addition of Coya Therapeutics, to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |